LAUREL OWENS: Open Payments
NPI 1104073907 · LEES SUMMIT, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$64,377 in 322 payments from 14 companies in 2025. Trend: 2023 $48,151 · 2024 $42,354 · 2025 $64,377
Speaker / faculty: $37,870Consulting: $12,275Travel & lodging: $10,156Food & beverage: $4,076
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 111 | $45,166 |
| ABBVIE INC. | 50 | $17,225 |
| E.R. Squibb & Sons, L.L.C. | 44 | $414 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 31 | $390 |
| Vanda Pharmaceuticals Inc. | 14 | $284 |
| Teva Pharmaceuticals USA, Inc. | 21 | $213 |
| Lundbeck LLC | 11 | $178 |
| Otsuka America Pharmaceutical, Inc. | 20 | $165 |
| Neurocrine BioSciences, Inc. | 6 | $123 |
| Janssen Pharmaceuticals, Inc | 9 | $111 |
Products named: ARISTADA, LYBALVI, VRAYLAR, COBENFY, CAPLYTA, REXULTI, FANAPT, UZEDY.
Industry payments across MO — which companies pay providers there.
